Login to Your Account



Helmedix Lands Seed Funding to Back Helminth Peptide R&D

By Nuala Moran
Staff Writer

Tuesday, March 19, 2013
LONDON – Start-up Helmedix Pty Ltd. has raised A$1.25 million (US$1.29 million) in seed funding, providing a springboard to the commercialization of molecules based on immune-modulating peptides used by helminth parasites to suppress the immune response of their hosts.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription